Viruses as vaccine vectors for infectious diseases and cancer (original) (raw)

• Smith, G. L., Mackett, M. & Moss, B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302, 490–495 (1983).
  Article CAS PubMed Google Scholar
• Moss, B., Smith, G. L., Gerin, J. L. & Purcell, R. H. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311, 67–69 (1984). Along with reference 1, this is the first major study to use recombinant poxvirus as a potential vaccine for another infectious disease.
  Article CAS PubMed Google Scholar
• Peter, G. et al. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Pediatrics 104, 942–950 (1999).
  Article CAS PubMed Google Scholar
• Mayr, A., Hochstein-Mintzel, V. & Stickl, H. Passage history, properties, and applicability of the attenuated vaccinia virus strain, MVA. Infection 3, 6–14 (1975).
  Article Google Scholar
• Sutter, G. & Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA 89, 10847–10851 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Sutter, G., Wyatt, L. S., Foley, P. L., Bennink, J. R. & Moss, B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12, 1032–1040 (1994).
  Article CAS PubMed Google Scholar
• Tartaglia, J. et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217–232 (1992).
  Article CAS PubMed Google Scholar
• Ramirez, J. C., Gherardi, M. M. & Esteban, M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74, 923–933 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Hodge, J. W. et al. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 63, 7942–7949 (2003).
  CAS PubMed Google Scholar
• Schneider, J. et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med. 4, 397–402 (1998).
  Article CAS PubMed Google Scholar
• Hirsch, V. M. et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70, 3741–3752 (1996).
  CAS PubMed PubMed Central Google Scholar
• Mann, B. A. et al. Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons. J. Interferon Cytokine Res. 28, 367–380 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Stack, J. et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201, 1007–1018 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Bowie, A. G. & Unterholzner, L. Viral evasion and subversion of pattern-recognition receptor signalling. Nature Rev. Immunol. 8, 911–922 (2008). This article highlights the interactions between viruses and pattern-recognition receptors.
  Article CAS Google Scholar
• Alejo, A. et al. A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc. Natl Acad. Sci. USA 103, 5995–6000 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Alcami, A. New insights into the subversion of the chemokine system by poxviruses. Eur. J. Immunol. 37, 880–883 (2007).
  Article CAS PubMed Google Scholar
• Alcami, A. & Smith, G. L. A soluble receptor for interleukin-1β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71, 153–167 (1992).
  Article CAS PubMed Google Scholar
• Blair, G. E. & Blair-Zajdel, M. E. Evasion of the immune system by adenoviruses. Curr. Top. Microbiol. Immunol. 273, 3–28 (2004).
  CAS PubMed Google Scholar
• Dasgupta, A., Hammarlund, E., Slifka, M. K. & Fruh, K. Cowpox virus evades CTL recognition and inhibits the intracellular transport of MHC class I molecules. J. Immunol. 178, 1654–1661 (2007).
  Article CAS PubMed Google Scholar
• Antoniou, A. N. & Powis, S. J. Pathogen evasion strategies for the major histocompatibility complex class I assembly pathway. Immunology 124, 1–12 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Meyer, H., Sutter, G. & Mayr, A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72, 1031–1038 (1991).
  Article CAS PubMed Google Scholar
• Blanchard, T. J., Alcami, A., Andrea, P. & Smith, G. L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79, 1159–1167 (1998).
  Article CAS PubMed Google Scholar
• Lehmann, M. H. et al. Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J. Virol. 83, 2540–2552 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Waibler, Z. et al. Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J. Virol. 83, 1563–1571 (2009).
  Article CAS PubMed Google Scholar
• Midgley, C. M., Putz, M. M., Weber, J. N. & Smith, G. L. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J. Gen. Virol. 89, 2992–2997 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Delaloye, J. et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 5, e1000480 (2009). This study identifies innate immune signalling pathways that are activated by MVA.
  Article PubMed PubMed Central CAS Google Scholar
• Mooij, P. et al. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J. Virol. 82, 2975–2988 (2008). This work uses different viral vectors to show that there is differential modulation of the vaccine-induced CD4+ and CD8+ T cell responses.
  Article CAS PubMed PubMed Central Google Scholar
• Cottingham, M. G. . et al. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS ONE 3, e1638 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Staib, C., Kisling, S., Erfle, V. & Sutter, G. Inactivation of the viral interleukin 1β receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J. Gen. Virol. 86, 1997–2006 (2005).
  Article CAS PubMed Google Scholar
• Fischer, M. A., Tscharke, D. C., Donohue, K. B., Truckenmiller, M. E. & Norbury, C. C. Reduction of vector gene expression increases foreign antigen-specific CD8+ T-cell priming. J. Gen. Virol. 88, 2378–2386 (2007).
  Article CAS PubMed Google Scholar
• McConkey, S. J. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Med. 9, 729–735 (2003).
  Article CAS PubMed Google Scholar
• Mwau, M. et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85, 911–919 (2004).
  Article CAS PubMed Google Scholar
• Keating, S. M. et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175, 5675–5680 (2005).
  Article CAS PubMed Google Scholar
• Lamoreaux, L., Roederer, M. & Koup, R. Intracellular cytokine optimization and standard operating procedure. Nature Protoc. 1, 1507–1516 (2006).
  Article CAS Google Scholar
• Vuola, J. M. et al. Differential immunogenicity of various heterologous prime–boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 174, 449–455 (2005).
  Article CAS PubMed Google Scholar
• Mooij, P. et al. Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding HIV-1 clade C immunogens. J. Virol. 83, 5881–5889 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Harari, A. et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205, 63–77 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Webster, D. P. et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl Acad. Sci. USA 102, 4836–4841 (2005). This paper illustrates the effect of heterologous prime–boost protocols in humans using viral-vector vaccines that lead to enhanced immunogenicity and protection against malaria infection.
  Article CAS PubMed PubMed Central Google Scholar
• Draper, S. J. et al. Effective induction of high-titer antibodies by viral vector vaccines. Nature Med. 14, 819–821 (2008). This article highlights the ability of certain viral-vector vaccine combinations to elicite antibody as well as T cell responses.
  Article CAS PubMed Google Scholar
• Liu, J. et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457, 87–91 (2009). This study describes the increased efficacy of heterologous adenoviral prime–boost regimes over homologous regimes for eliciting protection against a stringent SIV challenge in macaques, which suggests that such an approach should be adopted for HIV-1 vaccine development.
  Article CAS PubMed Google Scholar
• Shiver, J. W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331–335 (2002).
  Article CAS PubMed Google Scholar
• Gherardi, M. M. et al. Prime–boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J. Virol. 77, 7048–7057 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, S. et al. Potent specific immune responses induced by prime–boost–boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype, B. Vaccine 26, 6124–6131 (2008).
  Article CAS PubMed Google Scholar
• Lemckert, A. A. et al. Immunogenicity of heterologous prime–boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-Ad5 immunity. J. Virol. 79, 9694–9701 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Folgori, A. et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nature Med. 12, 190–197 (2006).
  Article CAS PubMed Google Scholar
• Fattori, E. et al. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming–boosting with novel adenoviral vectors based on different serotypes. Gene Ther. 13, 1088–1096 (2006).
  Article CAS PubMed Google Scholar
• Heeney, J. L. et al. A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens. J. Med. Primatol. 29, 268–273 (2000).
  Article CAS PubMed Google Scholar
• Koopman, G. et al. Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens. J. Gen. Virol. 85, 2915–2924 (2004). A report on the efficacy of a combination of three different vectors to elicit vaccine protection against SIV in macaques.
  Article CAS PubMed Google Scholar
• Darrah, P. A. et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nature Med. 13, 843–850 (2007). This work highlights the importance of measuring antigen-specific T cell quality and not just quantity when analysing immune responses for correlates of protection.
  Article CAS PubMed Google Scholar
• Forbes, E. K. et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol. 181, 4955–4964 (2008).
  Article CAS PubMed Google Scholar
• Beveridge, N. E. et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional _Mycobacterium tuberculosis_-specific CD4+ memory T lymphocyte populations. Eur. J. Immunol. 37, 3089–3100 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• McElrath, M.J. et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372, 1894–1905 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, J . et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime–boost regimens in rhesus monkeys. J. Virol. 82, 4844–4852 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Geiben-Lynn, R., Greenland, J. R., Frimpong-Boateng, K. & Letvin, N. L. Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses. Clin. Vaccine Immunol. 15, 691–696 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Jego, G. et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19, 225–234 (2003).
  Article CAS PubMed Google Scholar
• Xiang, Z. et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76, 2667–2675 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Hensley, S. E., Giles-Davis, W., McCoy, K. C., Weninger, W. & Ertl, H. C. Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J. Immunol. 175, 6032–6041 (2005).
  Article CAS PubMed Google Scholar
• Hensley, S. E. et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol. Ther. 15, 393–403 (2007).
  Article CAS PubMed Google Scholar
• Hornemann, S. et al. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J. Virol. 77, 8394–8407 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Ludwig, H. et al. Role of viral factor E3L in modified vaccinia virus Ankara infection of human HeLa cells: regulation of the virus life cycle and identification of differentially expressed host genes. J. Virol. 79, 2584–2596 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881–1893 (2008). Along with reference 52, this paper reports on the first Phase III clinical trial to use a T cell-based adenoviral vaccine vector in humans, and warns of the concerns of anti-HAdV-5 vector immunity.
  Article CAS PubMed PubMed Central Google Scholar
• Bradac, J. & Dieffenbach, C. W. HIV vaccine development: Lessons from the past, informing the future. IDrugs 12, 435–439 (2009).
  CAS PubMed Google Scholar
• Roberts, D. M. et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239–243 (2006). This study demonstrates that modification of viral surface proteins can increase the efficacy of HAdV-5-based vectors.
  Article CAS PubMed Google Scholar
• Tatsis, N. & Ertl, H. C. Adenoviruses as vaccine vectors. Mol. Ther. 10, 616–629 (2004).
  Article CAS PubMed Google Scholar
• Harro, C. et al. Safety and immunogenicity of the MRKAd5 and MRKAd6 HIV-1 trigene vaccines alone and in combination in healthy adults. Clin. Vaccine Immunol. 16, 1285–1292 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Tatsis, N. et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 13, 421–429 (2006).
  Article CAS PubMed Google Scholar
• Sridhar, S. et al. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron, A. J. Virol. 82, 3822–3833 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Farina, S. F. et al. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75, 11603–11613 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Reyes-Sandoval, A. et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur. J. Immunol. 38, 732–741 (2008).
  Article CAS PubMed Google Scholar
• Dudareva, M. et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27, 3501–3504 (2009).
  Article CAS PubMed Google Scholar
• Shen, X., Wong, S. B., Buck, C. B., Zhang, J. & Siliciano, R. F. Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J. Immunol. 169, 4222–4229 (2002).
  Article CAS PubMed Google Scholar
• Bronte, V. et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl Acad. Sci. USA 94, 3183–3188 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Tewalt, E. F. et al. Viral sequestration of antigen subverts cross presentation to CD8+ T cells. PLoS Pathog. 5, e1000457 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Moorthy, V.S. et al. Phase 1 evaluation of 3 highly immunogenic prime–boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis. 189, 2213–2219 (2004).
  Article CAS PubMed Google Scholar
• Yang, L., Bailey, L., Baltimore, D. & Wang, P. Targeting lentiviral vectors to specific cell types in vivo. Proc. Natl Acad. Sci. USA 103, 11479–11484 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Luo, X. M. et al. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 113, 1422–1431 (2008). This article describes the basis of engineering immunity with lentiviruses. These mediate gene transfer into human hematopoietic stem cells, which can then be differentiated in vitro into B cells that secrete neutralizing HIV-1 antibodies.
  Article PubMed CAS Google Scholar
• Garcia Casado, J. et al. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo. Eur. J. Immunol. 38, 1867–1876 (2008).
  Article PubMed CAS Google Scholar
• Yang, L. et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nature Biotech. 26, 326–334 (2008).
  Article CAS Google Scholar
• Meeusen, E.N., Walker, J., Peters, A., Pastoret, P. P. & Jungersen, G. Current status of veterinary vaccines. Clin. Microbiol. Rev. 20, 489–510 (2007). A summary of the current status of the viral vaccines that are in veterinary use.
  Article CAS PubMed PubMed Central Google Scholar
• Poulet, H. et al. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine 25, 5606–5612 (2007).
  Article CAS PubMed Google Scholar
• Swayne, D. E. & Kapczynski, D. Strategies and challenges for eliciting immunity against avian influenza virus in birds. Immunol. Rev. 225, 314–331 (2008).
  Article PubMed Google Scholar
• Steel, J. et al. A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus. Vaccine 26, 522–531 (2008).
  Article CAS PubMed Google Scholar
• Kitching, P. et al. Global FMD control — is it an option? Vaccine 25, 5660–5664 (2007).
  Article PubMed Google Scholar
• Pacheco, J. M., Brum, M. C., Moraes, M. P., Golde, W. T. & Grubman, M.J. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 337, 205–209 (2005).
  Article CAS PubMed Google Scholar
• Pena, L. et al. Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine. Vaccine 26, 5689–5699 (2008).
  Article CAS PubMed Google Scholar
• Minassian, A. M. & McShane, H. Tuberculosis vaccines: present and future. Expert Rev. Respir. Med. 2, 721–738 (2008).
  Article CAS PubMed Google Scholar
• Vordermeier, H. M., Huygen, K., Singh, M., Hewinson, R. G. & Xing, Z. Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing mycobacterial antigen 85A and Mycobacterium bovis BCG. Infect. Immun. 74, 1416–1418 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Vordermeier, H. M. et al. Cellular immune responses induced in cattle by heterologous prime–boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 112, 461–470 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Buddle, B. M. et al. Cattle as a model for development of vaccines against human tuberculosis. (Tuberculosis Edinb.) 85, 19–24 (2005).
  Article CAS PubMed Google Scholar
• Limbach, K. J. & Richie, T. L. Viral vectors in malaria vaccine development. Parasite Immunol. 31, 501–519 (2009).
  Article CAS PubMed Google Scholar
• Draper, S. J. et al. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe 5, 95–105 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hill, A. V. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nature Rev. Immunol. 6, 21–32 (2006).
  Article CAS Google Scholar
• Nwanegbo, E. et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11, 351–357 (2004).
  CAS PubMed PubMed Central Google Scholar
• Bejon, P. et al. A Phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin. Trials 1, e29 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• McShane, H. et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med. 10, 1240–1244 (2004). The first clinical study to demonstrate that immune responses primed by BCG can be boosted using a viral-vector system encoding an antigen from mycobacteria.
  Article CAS PubMed Google Scholar
• Hawkridge, T. et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J. Infect. Dis. 198, 544–552 (2008).
  Article PubMed Google Scholar
• Sander, C. R. et al. Safety and immunogenicity of a new TB vaccine, MVA85A, in M. tuberculosis infected individuals. Am. J. Respir. Crit. Care Med. 179, 724–733 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Radosevic, K. et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect. Immun. 75, 4105–4115 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Magalhaes, I. et al. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS ONE 3, e3790 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Hoft, D. F. et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J. Infect. Dis. 198, 1491–1501 (2008).
  Article PubMed Google Scholar
• Roukens, A. H. & Visser, L. G. Yellow fever vaccine: past, present and future. Expert Opin. Biol. Ther. 8, 1787–1795 (2008).
  Article CAS PubMed Google Scholar
• Pugachev, K. V., Guirakhoo, F., Trent, D. W. & Monath, T. P. Traditional and novel approaches to flavivirus vaccines. Int. J. Parasitol. 33, 567–582 (2003).
  Article CAS PubMed Google Scholar
• McAllister, A., Arbetman, A. E., Mandl, S., Pena-Rossi, C. & Andino, R. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J. Virol. 74, 9197–9205 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Bonaldo, M. C. et al. Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes. Virol. J. 4, 115 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Monath, T. P. et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20, 1004–1018 (2002).
  Article CAS PubMed Google Scholar
• McMichael, A. J., Gotch, F. M., Noble, G. R. & Beare, P. A. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309, 13–17 (1983).
  Article CAS PubMed Google Scholar
• Heeney, J. L. & Plotkin, S. A. Immunological correlates of protection from HIV infection and disease. Nature Immunol. 7, 1281–1284 (2006).
  Article CAS Google Scholar
• Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 19 November 2009 (doi: 10.1056/NEJMoa0908492). The first HIV-1 vaccine Phase III clinical trial reporting a modest trend of protection from infection.
  Article CAS Google Scholar
• Thongcharoen, P. et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J. Acquir. Immune Defic. Syndr. 46, 48–55 (2007).
  Article PubMed Google Scholar
• Sandstrom, E. et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198, 1482–1490 (2008).
  Article PubMed Google Scholar
• Priddy, F. H. et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46, 1769–1781 (2008).
  Article CAS PubMed Google Scholar
• Hansen, S. G_. et al_. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nature Med. 15, 293–299 (2009). This paper describes the use of CMV as an HIV-1 vaccine vector in macaques and shows that this vector can induce T cells with an effector memory phenotype that are associated with protection from a mucosal challenge with SIV.
  Article CAS PubMed Google Scholar
• Wilson, N. A. et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 80, 5875–5885 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Casimiro, D. R. et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77, 6305–6313 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Ward, S., Copier, J. & Dalgleish, A. Technical challenges facing therapeutic cancer vaccines. Curr. Opin. Drug Discov. Devel. 11, 168–177 (2008).
  CAS PubMed Google Scholar
• Emens, L. A. Cancer vaccines: on the threshold of success. Expert Opin. Emerg. Drugs 13, 295–308 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hodge, J. W., Guha, C., Neefjes, J. & Gulley, J. L. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology 22, 1064–1070; discussion 1075, 1080–1081, 1084 (2008).
  PubMed Google Scholar
• Kaufman, H. L. et al. Phase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J. Transl. Med. 7, 2 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Ramlau, R. et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J. Thorac. Oncol. 3, 735–744 (2008).
  Article PubMed Google Scholar
• Dreicer, R. et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest. New Drugs 27, 379–386 (2009).
  Article CAS PubMed Google Scholar
• Quoix, E. et al. Randomized, controlled phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL-2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Ann. Oncol. 19, viii92 (2008).
  Google Scholar
• Salucci, V. et al. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand. Scand. J. Immunol. 63, 35–41 (2006).
  Article CAS PubMed Google Scholar
• Aurisicchio, L. et al. Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int. J. Cancer 120, 2290–2300 (2007).
  Article CAS PubMed Google Scholar
• Domi, A. & Moss, B. Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage λ-based recombination. Nature Methods 2, 95–97 (2005).
  Article CAS PubMed Google Scholar
• Stanton, R. J., McSharry, B. P., Armstrong, M., Tomasec, P. & Wilkinson, G. W. Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques 45, 659–662, 664–668 (2008). This article shows how toxic transgenes can be switched off during the production of adenoviral-vector vaccines in cell culture, thereby enabling the growth and generation of recombinant AdV vaccines encoding such toxic proteins.
  Article CAS PubMed Google Scholar
• Paton, D. J. et al. Application of non-structural protein antibody tests in substantiating freedom from foot-and-mouth disease virus infection after emergency vaccination of cattle. Vaccine 24, 6503–6512 (2006).
  Article CAS PubMed Google Scholar
• Ko, S. Y. et al. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors. J. Virol. 83, 748–756 (2009).
  Article CAS PubMed Google Scholar
• Gallego-Gomez, J. C. et al. Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J. Virol. 77, 10606–10622 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Smith, G. L., Vanderplasschen, A. & Law, M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83, 2915–2931 (2002).
  Article CAS PubMed Google Scholar
• Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365–396 (1998).
  Article CAS PubMed Google Scholar
• Gaggar, A., Shayakhmetov, D. M. & Lieber, A. CD46 is a cellular receptor for group B adenoviruses. Nature Med. 9, 1408–1412 (2003).
  Article CAS PubMed Google Scholar
• Cheng, C. et al. Mechanism of Ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog. 3, e25 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Ghosh-Choudhury, G., Haj-Ahmad, Y., Brinkley, P., Rudy, J. & Graham, F. L. Human adenovirus cloning vectors based on infectious bacterial plasmids. Gene 50, 161–171 (1986).
  Article CAS PubMed Google Scholar
• Bett, A. J., Haddara, W., Prevec, L. & Graham, F. L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl Acad. Sci. USA 91, 8802–8806 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Smith, G. L. & Moss, B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 25, 21–28 (1983).
  Article CAS PubMed Google Scholar
• Liu, X., Kremer, M. & Broyles, S. S. A natural vaccinia virus promoter with exceptional capacity to direct protein synthesis. J. Virol. Methods 122, 141–145 (2004).
  Article CAS PubMed Google Scholar
• Crucell & AERAS. Aeras and Crucell announce TB vaccine clinical trial in Kenya; promising vaccine candidate advances to Phase II safety study in South Africa. Crucell [online], (2008).